Khalaf Hatem, El-Meteini Mahmoud, El-Sefi Talaat, Hamza Alaa F, El-Gazaz Galal, Saleh Saleh M, Moustafa Ibrahim, Gad Hesham, Yosry Ayman, El-Hussainy Ehab, Khafaga Medhat, Helmy Amr
Department of Liver Transplantation and Hepatobiliary-Pancreatic Surgery MBC-72, King Faisal Specialist Hospital and Research Center, PO Box 3354, Riyadh 11211, Kingdom of Saudi Arabia.
Saudi Med J. 2005 Sep;26(9):1394-7.
To date, cadaveric organ donation is illegal in Egypt. Therefore, Egypt recently introduced living donor liver transplantation (LDLT), aiming to save those who are suffering from end stage liver disease. Herein, we study the evolution of LDLT in Egypt.
In Egypt, between August 2001 and February 2004, we approached all centers performing LDLT through personal communication and sent a questionnaire to each center asking for limited information regarding their LDLT experience.
We identified and approached 7 LDLT centers, which collectively performed a total of 130 LDLT procedures, however, 3 major centers performed most of the cases (91%). Overseas surgical teams, mainly from Japan, France, Korea, and Germany, either performed or supervised almost all procedures. Out of those 7 LDLT centers, 5 centers agreed to provide complete data on their patients including a total of 73 LDLT procedures. Out of those 73 recipients, 50 (68.5%) survived after a median follow-up period of 305 days (range 15-826 days). They reported single donor mortality. Hepatitis C virus cirrhosis, whether alone or mixed with schistosomiasis, was the main indication for LDLT.
Egypt recently introduced LDLT with reasonable outcomes; yet, it carries considerable risks to healthy donors, it lacks cadaveric back up, and is not feasible for all patients. We hope that the initial success in LDLT will not deter the efforts to legalize cadaveric organ donation in Egypt.
迄今为止,尸体器官捐赠在埃及是非法的。因此,埃及最近引入了活体肝移植(LDLT),旨在挽救那些患有终末期肝病的患者。在此,我们研究埃及活体肝移植的发展情况。
在2001年8月至2004年2月期间,我们通过个人沟通联系了埃及所有开展活体肝移植的中心,并向每个中心发送了一份问卷,询问有关其活体肝移植经验的有限信息。
我们识别并联系了7个活体肝移植中心,这些中心总共进行了130例活体肝移植手术,然而,3个主要中心完成了大部分病例(91%)。海外手术团队,主要来自日本、法国、韩国和德国,实施或监督了几乎所有手术。在这7个活体肝移植中心中,5个中心同意提供其患者的完整数据,包括总共73例活体肝移植手术。在这73名受者中,50名(68.5%)在中位随访期305天(范围15 - 826天)后存活。他们报告了供者单例死亡情况。丙型肝炎病毒肝硬化,无论单独存在还是与血吸虫病混合存在,都是活体肝移植的主要适应证。
埃及最近引入了活体肝移植,取得了合理的结果;然而,这对健康供者有相当大的风险,缺乏尸体器官作为后备,且并非对所有患者都可行。我们希望活体肝移植的初步成功不会阻碍埃及尸体器官捐赠合法化的努力。